Published results describe the use of point-of-care imaging for the early detection and proactive treatment of wound-related cellulite
MolecuLight Inc., the leader in point-of-care fluorescence imaging for the real-time detection of wounds with increased bacterial load, announced the publication in the International Wound Journal1 of an independent prospective observational study of the effects of ingestion of the Fluorescence imaging should be studied in the standard of care for the diagnosis and treatment of wound-related cellulite. Dr. Charles Andersen, a surgeon at Madigan Army Medical Center, led this study of wound-related cellulite, which is defined as the invasion of the adjacent dermis by bacteria from chronic wounds.
The publication entitled “Diagnosing and Treating the Invasive Spread of Bacteria (Cellulitis) from Chronic Wounds Using Point-of-Care Fluorescence Imaging” included 236 patients who were outpatient between January 2020 and April 2021 over a period of 16 months Visited Madigan Wound Care Center. In the study, 6.4% (15/236) of patients were diagnosed with wound-related cellulitis. All patients diagnosed with wound-related cellulitis had an irregular pattern of red (bacterial) fluorescence, visualized with the MolecuLight i: X Point-of-Care Imaging System, extending beyond the wound bed and surrounding area. This unique pattern of red fluorescence could not be removed by cleaning or debridement.
Cellulitis is a serious clinical condition that accounts for 10% of all infection-related hospital stays in the United States2 and costs up to $ 3.7 billion annually3. Cellulitis can lead to serious complications such as bacteremia, necrotizing fasciitis, endocarditis or shock4,3. Severe cellulite in patients with other comorbidities can lead to death. Timely and accurate diagnosis of cellulitis is known to be difficult because there are no gold standard diagnostic techniques and the clinical picture is similar to that of other inflammatory diseases (e.g., congestive dermatitis). 85% of patients with misdiagnosis go to avoidable hospitalization and 92% receive unnecessary antibiotics5.
“The results of this study show that MolecuLight imaging at the point-of-care is an interesting solution to detect the spread of bacteria in tissue, reduce misdiagnosis of wound-associated cellulite, and enable more proactive early treatment, especially in patients without it obvious symptoms, “says Dr. Charles A. Andersen, Director of Vascular / Endovascular and Limb Conservation Surgery Service (Retired), Director of Wound Care Services, and Medical Director of the Wound Care Clinic at Madigan Army Medical Center, Tacoma, Washington. “Given that at least 30% of cellulite cases are misdiagnosed, 6,5 the addition of consistent and objective information provided by fluorescent scanning can greatly reduce the uncertainty associated with diagnosing wound-related cellulitis Using fluorescent imaging to aid earlier detection and proactive treatment of wound-related cellulite will limit infection progression and avoid the need for intravenous antibiotics and the high costs associated with hospitalization. “
An example of wound-related cellulitis from the study is shown (above) where the wound appears to have neither cellulitis nor increased bacterial load when assessed using standard clinical signs and symptoms (left). In contrast, when taking a picture with the MolecuLight i: X (right), an irregular pattern of red (bacterial) fluorescence is visible that extends beyond the wound bed and the wound area and could not be removed even by vigorous cleaning, which suggests that that the bacteria are below the surface. This pattern of red fluorescence, indicating invasive spread of the bacteria into surrounding tissue, was the same for all wounds in the study diagnosed as wound-related cellulitis.
Dr. Andersen will present the results of this publication in a talk entitled “Diagnosing and Treating the Invasive Spread of Bacteria (Cellulitis) from Chronic Wounds Using Point-of-Care Fluorescence Imaging” at the upcoming SAWC (Symposium on Advanced Wound Care) Fall 2021% 2BFall% 2B2021 & a = SAWC + (Symposium + on + Advanced + Wound + Care) + Fall + 2021) Fall 2021 on Sunday, October 31, 2021 at 9:00 a.m. at Caesars Palace in Las Vegas, Nevada , introduce.
1 Andersen, C.A. et al, “Diagnosis and Treatment of the Invasive
Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing
Point-of-Care Fluorescence Imaging”, International Wound Journal 2021:
2 Lazzarini L et al, J Infect. 2005; 51 (5): 383-389.
3 Raff AB et al, JAMA. 2016; 316 (3): 325-337.
4 Pasternack MS. Mandell, Douglas, & Bennett’s Principles &
Practice of Infectious Diseases. Vol 1; Phil., PA: Churchill
5 Weng QY et al, JAMA Dermatol. 2017; 153 (2): 141-146.
6 Levell NJ et al, Br J Dermatol. 2011;164(6):1326-1328.
About MolecuLight Inc.
MolecuLight Inc., a privately held medical imaging company, develops and markets its proprietary fluorescence imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i: X fluorescence imaging system and accessories, provide the global wound care market with a point-of-care hand-held imaging device for the detection of wounds with increased bacterial load (when used with clinical signs and symptoms) and for digital wound measurement. The company also markets its unique fluorescence imaging platform technology to other markets with globally relevant, unmet needs, including food safety, consumer cosmetics and other key industrial markets.
Download from: https://moleculight.box.com/s/oab22c1vi8ud1j8oymylbfogp2lg12bk
Photo – https://mma.prnewswire.com/media/1656706/MolecuLight_Study_of_236_patients_reveals_utility_of_MolecuLight.jpg
Original content by: MolecuLight Inc., transmitted by news aktuell
Original message: https://www.presseportal.de/pm/135706/5043741